

Yumei Jia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1781720/publications.pdf>

Version: 2024-02-01

13
papers

141
citations

1306789

7
h-index

1281420

11
g-index

13
all docs

13
docs citations

13
times ranked

223
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-linear associations of body mass index with impaired fasting glucose, β -cell dysfunction, and insulin resistance in nondiabetic Chinese individuals: a cross-sectional study. <i>Endokrynologia Polska</i> , 2021, , .	0.3	2
2	Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.	1.0	14
3	Irisin as a Potential Biomarker Associated with Myocardial Injuries in Patients with Severe Hypothyroidism. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-8.	0.6	3
4	Levothyroxine Replacement Alleviates Thyroid Destruction in Hypothyroid Patients With Autoimmune Thyroiditis: Evidence From a Thyroid MRI Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 138.	1.5	5
5	Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit. <i>Shock</i> , 2019, 51, 289-297.	1.0	31
6	Magnetic resonance T1-mapping evaluates the degree of thyroid destruction in patients with autoimmune thyroiditis. <i>Endocrine Connections</i> , 2018, 7, 1315-1321.	0.8	3
7	Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. <i>Diabetes Therapy</i> , 2017, 8, 309-319.	1.2	3
8	PPAR- α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study. <i>Diabetes Therapy</i> , 2017, 8, 433-444.	1.2	8
9	Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-6.	0.6	8
10	PPAR- α Agonist Fenofibrate Reduced the Secreting Load of β -Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance. <i>PPAR Research</i> , 2016, 2016, 1-7.	1.1	5
11	PPAR- α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. <i>Medical Science Monitor</i> , 2016, 22, 743-751.	0.5	21
12	Native Magnetic Resonance T1-Mapping Identifies Diffuse Myocardial Injury in Hypothyroidism. <i>PLoS ONE</i> , 2016, 11, e0151266.	1.1	21
13	PPAR- α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. <i>PPAR Research</i> , 2015, 2015, 1-8.	1.1	17